Setting new standards in information exchange for the pharmaceutical and biotech industry
Immuno-Oncology in the Headlines Again with Historic Bristol-Myers Purchase of Nektar Drug
February 16, 2018
The intense focus on the huge potential of immuno-oncology to fight cancer continues to grow. In the latest record-breaking deal, Bristol-Myers Squibb has agreed to pay $1.85 billion to small biotech start-up Nektar Therapeutics for the rights to its experimental cancer drug NKTR-214, as recently reported in several industry and business outlets, including Forbes.
If the drug reaches the market, Nektar will receive 65% of global profits and Bristol-Myers 35%. This unprecedented deal in up-front partnership fees for a minority stake in a single development stage biotech drug demonstrates once more the significance of immuno-oncology in the marketplace.
After successfully wrapping up our 4th annual Immuno-Oncology 360° conference in New York on February 7-9, 2018, which brought together stakeholders from GSK, the National Cancer Institute, Citi, SITC, Merck, Novartis, Roche and many other parties across the entire IO community, we look forward to continuing our coverage of this vital space. Our next IO conference is Rational Combinations 360°, which takes place on September 13-14, 2018 in Philadelphia, PA.